DE602007000856D1 - Weichkapseln mit palonosetron-hydrochlorid mit verbesserter stabilität und bioverfügbarkeit - Google Patents

Weichkapseln mit palonosetron-hydrochlorid mit verbesserter stabilität und bioverfügbarkeit

Info

Publication number
DE602007000856D1
DE602007000856D1 DE602007000856T DE602007000856T DE602007000856D1 DE 602007000856 D1 DE602007000856 D1 DE 602007000856D1 DE 602007000856 T DE602007000856 T DE 602007000856T DE 602007000856 T DE602007000856 T DE 602007000856T DE 602007000856 D1 DE602007000856 D1 DE 602007000856D1
Authority
DE
Germany
Prior art keywords
palonosetrono
bioavailability
hydrochloride
improved stability
soft capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007000856T
Other languages
English (en)
Inventor
Daniele Bonadeo
Giorgio Calderari
Enrico Braglia
Riccardo Braglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007000856(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Publication of DE602007000856D1 publication Critical patent/DE602007000856D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
DE602007000856T 2006-10-24 2007-10-19 Weichkapseln mit palonosetron-hydrochlorid mit verbesserter stabilität und bioverfügbarkeit Active DE602007000856D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24
PCT/EP2007/009098 WO2008049552A1 (en) 2006-10-24 2007-10-19 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Publications (1)

Publication Number Publication Date
DE602007000856D1 true DE602007000856D1 (de) 2009-05-20

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007000856T Active DE602007000856D1 (de) 2006-10-24 2007-10-19 Weichkapseln mit palonosetron-hydrochlorid mit verbesserter stabilität und bioverfügbarkeit

Country Status (36)

Country Link
US (2) US20080152704A1 (de)
EP (1) EP1940366B9 (de)
JP (1) JP5144527B2 (de)
KR (1) KR101441459B1 (de)
CN (1) CN101573106B (de)
AR (1) AR063362A1 (de)
AT (1) ATE427742T1 (de)
AU (1) AU2007308378B2 (de)
BR (1) BRPI0718497B1 (de)
CA (1) CA2666512C (de)
CL (1) CL2007003055A1 (de)
CO (1) CO6160289A2 (de)
CR (1) CR10728A (de)
CY (1) CY1109914T1 (de)
DE (1) DE602007000856D1 (de)
DK (1) DK1940366T3 (de)
EA (1) EA016455B1 (de)
ES (1) ES2325339T3 (de)
GT (1) GT200900096A (de)
HK (1) HK1117769A1 (de)
HN (1) HN2009000785A (de)
HR (1) HRP20090341T1 (de)
IL (1) IL198225A (de)
ME (1) ME01949B (de)
MX (1) MX2009004461A (de)
NO (1) NO342353B1 (de)
NZ (1) NZ576237A (de)
PL (1) PL1940366T3 (de)
PT (1) PT1940366E (de)
RS (1) RS50842B (de)
SI (1) SI1940366T1 (de)
SV (1) SV2009003238A (de)
TW (1) TWI367212B (de)
UA (1) UA97653C2 (de)
WO (1) WO2008049552A1 (de)
ZA (1) ZA200902773B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5787301B2 (ja) * 2006-01-27 2015-09-30 アデア ファーマシューティカルズ，インコーポレイテッド 弱塩基性薬および有機酸を含む薬物送達系
EP2363117B1 (de) * 2006-01-27 2015-08-19 Aptalis Pharmatech, Inc. Arzneimittelzubereitung mit schwach basischem selektivem 5-HT3 Blocker und organischen Säuren
US20100143461A1 (en) * 2008-12-08 2010-06-10 Ben-Zion Solomon Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
WO2011058427A1 (en) 2009-11-13 2011-05-19 Helsinn Healthcare S.A. Palonosetron metabolites
ES2595077T3 (es) * 2009-11-18 2016-12-27 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (de) 2009-11-18 2016-07-06 Helsinn Healthcare SA Zusammensetzungen zur Behandlung von zentral vermitteltem Unwohlsein und Erbrechen
PL2744497T3 (pl) 2011-10-18 2016-10-31 Terapeutyczne połączenia netupitantu i palonosetronu
CN103446072A (zh) * 2012-06-02 2013-12-18 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
ES2692881T3 (es) * 2013-03-19 2018-12-05 Galenicum Health S.L. Composiciones farmacéuticas que comprenden un agente activo
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP2017504615A (ja) 2013-12-23 2017-02-09 サムヤン バイオファーマシューティカルズ コーポレイション パロノセトロンを含有する薬学組成物
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
DE3650772T2 (de) * 1985-04-27 2003-04-03 Hoffmann La Roche Derivate von Indazole-3-carboxamide und -3-carboxylsäure
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
AU642178B2 (en) * 1989-11-28 1993-10-14 Roche Palo Alto Llc New tricyclic compounds
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
TWI367212B (en) 2012-07-01
NO20091945L (no) 2009-05-25
KR20090073234A (ko) 2009-07-02
TW200827355A (en) 2008-07-01
WO2008049552A1 (en) 2008-05-02
US20170035748A1 (en) 2017-02-09
AU2007308378A1 (en) 2008-05-02
ME01949B (me) 2010-08-31
CN101573106A (zh) 2009-11-04
NZ576237A (en) 2011-12-22
IL198225A0 (en) 2009-12-24
PL1940366T3 (pl) 2009-09-30
NO342353B1 (no) 2018-05-07
EP1940366B9 (de) 2009-12-02
HK1117769A1 (en) 2009-01-23
BRPI0718497B1 (pt) 2024-02-06
CO6160289A2 (es) 2010-05-20
EA016455B1 (ru) 2012-05-30
CL2007003055A1 (es) 2008-03-24
CY1109914T1 (el) 2014-09-10
ATE427742T1 (de) 2009-04-15
AR063362A1 (es) 2009-01-21
SV2009003238A (es) 2009-11-09
UA97653C2 (ru) 2012-03-12
DK1940366T3 (da) 2009-06-29
MX2009004461A (es) 2009-09-16
HRP20090341T1 (en) 2009-07-31
HN2009000785A (es) 2011-10-14
PT1940366E (pt) 2009-06-17
KR101441459B1 (ko) 2014-09-18
US20080152704A1 (en) 2008-06-26
CA2666512C (en) 2014-05-27
GT200900096A (es) 2011-08-29
ES2325339T3 (es) 2009-09-01
SI1940366T1 (sl) 2009-08-31
CR10728A (es) 2009-07-23
CN101573106B (zh) 2013-07-24
EP1940366B1 (de) 2009-04-08
BRPI0718497A2 (pt) 2014-07-08
IL198225A (en) 2013-03-24
EP1940366A1 (de) 2008-07-09
RS50842B (sr) 2010-08-31
AU2007308378B2 (en) 2013-02-21
JP5144527B2 (ja) 2013-02-13
EA200970396A1 (ru) 2009-10-30
ZA200902773B (en) 2010-03-31
CA2666512A1 (en) 2008-05-02
JP2009507933A (ja) 2009-02-26

Similar Documents

Publication Publication Date Title
DE602007000856D1 (de) Weichkapseln mit palonosetron-hydrochlorid mit verbesserter stabilität und bioverfügbarkeit
NL301176I2 (nl) Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan
NO2017033I1 (no) baricitinib og farmasøytisk akseptable salter derav
DK1858490T3 (da) Lægemiddelformer med forbedrede farmakokinetiske egenskaber
ATE452839T1 (de) Kapsel mit reduziertem nachtropfen
DE602006007875D1 (de) Kapseln
NL300690I2 (nl) Lurasidon hydrochloride
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
EP2084519A4 (de) Fortgeschrittene arzneistoffentwicklung und herstellung
DK1957073T3 (da) Lægemiddel
CR10697A (es) Rellenos
DK1856051T3 (da) Amorft lercanidipinhydrochlorid
DE602005007987D1 (de) achtelung und -entschachtelung
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
ITMI20050167U1 (it) Cuscino
DE112007001763A5 (de) Schaltungsanordnung
AT504332B8 (de) Chokerseil und chokerseilsystem
SE0400990D0 (sv) Läkemedel
FI20060582A0 (fi) Farmaseuttinen valmiste
FI20040558A0 (fi) Farmaseuttinen valmiste
FI20071023A0 (fi) Forma
GB0619309D0 (en) Cyclic amine derivatives and their uses
UA10054S (uk) Упаковка фармацевтичного засобу
UA10843S (uk) Упаковка фармацевтичного засобу

Legal Events

Date Code Title Description
8364 No opposition during term of opposition